These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 25611566)

  • 1. Plasma amino acid profiling in major depressive disorder treated with selective serotonin reuptake inhibitors.
    Woo HI; Chun MR; Yang JS; Lim SW; Kim MJ; Kim SW; Myung WJ; Kim DK; Lee SY
    CNS Neurosci Ther; 2015 May; 21(5):417-24. PubMed ID: 25611566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma levels of interleukin-6 and selective serotonin reuptake inhibitor response in patients with major depressive disorder.
    Yoshimura R; Hori H; Ikenouchi-Sugita A; Umene-Nakano W; Katsuki A; Atake K; Nakamura J
    Hum Psychopharmacol; 2013 Sep; 28(5):466-70. PubMed ID: 23813968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saliva levels of 3-methoxy-4-hydroxyphenylglycol and clinical efficacy of mirtazapine or selective serotonin reuptake inhibitors in patients with major depression.
    Egami M; Imamura Y; Nabeta H; Mizoguchi Y; Yamada S
    Hum Psychopharmacol; 2013 Jan; 28(1):7-14. PubMed ID: 23124792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma serotonin levels are associated with antidepressant response to SSRIs.
    Holck A; Wolkowitz OM; Mellon SH; Reus VI; Nelson JC; Westrin Å; Lindqvist D
    J Affect Disord; 2019 May; 250():65-70. PubMed ID: 30831543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
    Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.
    Wu EQ; Yu AP; Lauzon V; Ramakrishnan K; Marynchenko M; Ben-Hamadi R; Blum S; Erder MH
    Ann Pharmacother; 2011 Apr; 45(4):441-51. PubMed ID: 21415162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Female sexual dysfunction in patients with major depressive disorder (MDD) treated with selective serotonin reuptake inhibitor (SSRI) and its association with serotonin 2A-1438 G/A single nucleotide polymorphisms.
    Masiran R; Sidi H; Mohamed Z; Mohd Nazree NE; Nik Jaafar NR; Midin M; Das S; Mohamed Saini S
    J Sex Med; 2014 Apr; 11(4):1047-1055. PubMed ID: 24533444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diminished functional properties of T regulatory cells in major depressive disorder: The influence of selective serotonin reuptake inhibitor.
    Jahangard L; Behzad M
    J Neuroimmunol; 2020 Jul; 344():577250. PubMed ID: 32344162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors in Pediatric Major Depressive Disorder.
    Varigonda AL; Jakubovski E; Taylor MJ; Freemantle N; Coughlin C; Bloch MH
    J Am Acad Child Adolesc Psychiatry; 2015 Jul; 54(7):557-64. PubMed ID: 26088660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of selective serotonin reuptake inhibitor treatment on plasma oxytocin and cortisol in major depressive disorder.
    Keating C; Dawood T; Barton DA; Lambert GW; Tilbrook AJ
    BMC Psychiatry; 2013 Apr; 13():124. PubMed ID: 23627666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder - an experimental medicine blinded controlled trial.
    Knorr UB
    Dan Med J; 2012 Apr; 59(4):B4426. PubMed ID: 22459724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
    Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC
    Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
    Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
    BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder.
    Papakostas GI; Fava M
    Eur Neuropsychopharmacol; 2007 Jan; 17(1):32-6. PubMed ID: 16762534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of interleukin-6 and serotonin as biomarkers to predict response to fluoxetine.
    Manoharan A; Rajkumar RP; Shewade DG; Sundaram R; Muthuramalingam A; Paul A
    Hum Psychopharmacol; 2016 May; 31(3):178-84. PubMed ID: 27018372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated levels of glutathionyl haemoglobin as an oxidative stress marker in patients with major depressive disorder.
    Mathew B; Srinivasan K; Johnson P; Thomas T; Mandal AK
    Indian J Med Res; 2019 Apr; 149(4):497-502. PubMed ID: 31411173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.
    Papakostas GI; Thase ME; Fava M; Nelson JC; Shelton RC
    Biol Psychiatry; 2007 Dec; 62(11):1217-27. PubMed ID: 17588546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life.
    Seripa D; Pilotto A; Paroni G; Fontana A; D'Onofrio G; Gravina C; Urbano M; Cascavilla L; Paris F; Panza F; Padovani A; Pilotto A
    J Psychopharmacol; 2015 May; 29(5):623-33. PubMed ID: 25827644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Klotho Gene and Selective Serotonin Reuptake Inhibitors: Response to Treatment in Late-Life Major Depressive Disorder.
    Paroni G; Seripa D; Fontana A; D'Onofrio G; Gravina C; Urbano M; Addante F; Lozupone M; Copetti M; Pilotto A; Greco A; Panza F
    Mol Neurobiol; 2017 Mar; 54(2):1340-1351. PubMed ID: 26843110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies.
    Papakostas GI; Cooper-Kazaz R; Appelhof BC; Posternak MA; Johnson DP; Klibanski A; Lerer B; Fava M
    Int Clin Psychopharmacol; 2009 Jan; 24(1):19-25. PubMed ID: 19092448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.